Quoin says QRX003 pediatric compassionate-use case report accepted for publication in Dermatology and Therapy

Bitget2026/10/06 10:30

Quoin Pharmaceuticals announced acceptance of a peer-reviewed paper on QRX003 for Netherton syndrome in Dermatology and Therapy. Results were already presented in the manuscript, including a pediatric compassionate-use case report describing fully healed skin and elimination of itch. Prior updates cited improving outcomes across enrolled pediatric compassionate-use patients, with no treatment-related adverse events reported. Interim Phase 2/3 trial results disclosed in August showed most early participants improved on the study’s main clinical assessment. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060630PRIMZONEFULLFEED9840001) on October 06, 2026, and is solely responsible for the information contained therein.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Quoin Pharmaceuticals announced acceptance of a peer-reviewed paper on QRX003 for Netherton syndrome in Dermatology and Therapy.
Results were already presented in the manuscript, including a pediatric compassionate-use case report describing fully healed skin and elimination of itch.
Prior updates cited improving outcomes across enrolled pediatric compassionate-use patients, with no treatment-related adverse events reported.
Interim Phase 2/3 trial results disclosed in August showed most early participants improved on the study’s main clinical assessment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060630PRIMZONEFULLFEED9840001) on October 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.

华尔街见闻•2026/11/09 10:26